APLS: Roth Capital Initiates Coverage with 'Buy' Rating at $31
Roth Capital announced the initiation of coverage on Apellis Pharmaceuticals (APLS) with a 'Buy' rating. Analyst Adam Walsh set a price target of $31.00 USD. This marks a significant update as the previous rating was a 'Sell'.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.